Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 10, 2026

AstraZeneca results: FY and Q4 2025

View original at finance.yahoo.com
AstraZeneca results: FY and Q4 2025 Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period CAMBRIDGE, England, February 10, 2026--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary FY 2025 % Change Q4 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Total Revenue is expected to increase by a mid-to-high single-digit percentage for FY 2026 at CER

    80% confidence

  • Core EPS is expected to increase by a low double-digit percentage for FY 2026 at CER

    80% confidence

  • Transformative technologies including substantial and growing number of trials have the potential to revolutionise outcomes for patients and drive growth well beyond 2030

    80% confidence

  • Core Tax rate is expected to be between 18-22% for FY 2026

    80% confidence

  • The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing.

    80% confidence

  • Harmonised listing structure across NYSE, London, and Stockholm exchanges enables more shareholders to participate in the company's exciting future

    80% confidence

  • In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.

    80% confidence

Data points we hold from this source

AstraZeneca AB · phase 3 trials ongoing100 trials
AstraZeneca AB · positive phase 3 readouts16 trials
AstraZeneca AB · product revenue58640 million_USD
AstraZeneca AB · product sales55573 million_USD
AstraZeneca AB · core sga expense4453 million_USD
AstraZeneca AB · rd expense3862 million_USD
AstraZeneca AB · operating profit2978 million_USD
AstraZeneca AB · revenue58739 million_USD
AstraZeneca AB · revenue15503 million_USD
AstraZeneca AB · second interim dividend2.17 USD
AstraZeneca AB · sga expense5492 million_USD
AstraZeneca AB · core operating profit4098 million_USD
AstraZeneca AB · core operating margin26 percent
AstraZeneca AB · dividend per share3.20 USD
AstraZeneca AB · gross margin80 percent
AstraZeneca AB · blockbuster medicines16 products
AstraZeneca AB · core tax rate14 percent
AstraZeneca AB · net finance expense349 million_USD
AstraZeneca AB · operating margin19 percent
AstraZeneca AB · tax rate11 percent
AstraZeneca AB · core eps9.16 USD
AstraZeneca AB · alliance revenue959 million_USD
AstraZeneca AB · collaboration revenue99 million_USD
AstraZeneca AB · approvals in major regions43 approvals
AstraZeneca AB · core rd expense3731 million_USD